Neuro News Roundup: Potential MS Therapies
Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.
Amiselimod, a second generation spin-off of fingolimod, may be a new potential treatment in MS and potentially other immune-mediated inflammatory diseases. Alemtuzumab may be a useful addition to the armamentarium as first-line treatment for relapsing-remitting MS (RRMS). Arbaclofen extended-release tablets may be more effective at decreasing spasticity related to MS than the commonly used spasticity-fighting drug baclofen.
Related Videos
Related Content
